- This financing round was led by OrbiMed, with participation from TCGX, Lilly Asia Ventures (LAV), Qianji Capital, and existing shareholders Shenzhen Capital Group and Yuanhe Holdings.
- The proceeds will be used to advance multiple pipeline candidates, including AC-101, a global leading RIPK2 inhibitor for the treatment of ulcerative colitis.
New York and Suzhou, ChinaMay 18, 2026 /PRNewswire/ — Accro Bioscience Co., Ltd. (“Accro Bioscience”), a clinical-stage biotechnology company focused on “regulated cell death,” announced the completion of a $50 million Series C financing round. The round was led by OrbiMed, with participation from TCG Crossover (“TCGX”), Lilly Asia Ventures (“LAV”), Qianji Capital, and existing shareholders Shenzhen Capital Group and Yuanhe Holdings.
The financing will be used to advance a Phase IIb clinical trial of AC-101, a global leading RIPK2 inhibitor for the treatment of ulcerative colitis (UC), and to accelerate the development of other pipeline programs in inflammation and immune diseases.
Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience, said: “Accro has always been dedicated to one mission — bringing innovative oral therapies to millions of patients worldwide suffering from immune-mediated diseases. We sincerely thank our investors who share our vision and continue to support us.”
Dr. Dasong Wang, Partner at OrbiMed, said: “We are deeply impressed by Accro’s pipeline. The team’s scientific strength and outstanding execution were key factors in our investment decision. We are delighted to collaborate with Accro to accelerate its global clinical development.”